SLU-PP-332 Peptide

SLU-PP-332 acts through the ERR pathway (estrogen-related receptors) while AICAR works through AMPK. SLU-PP-332 specifically increases fatigue-resistant muscle fiber types and mitochondrial biogenesis, representing a different exercise-mimetic mechanism.

SLU-PP-332 is a small molecule (not a peptide), but it is included in our catalog as a research compound relevant to metabolic and exercise physiology research alongside peptide-based exercise mimetics.

SLU-PP-332 is a synthetic small-molecule pan-agonist of the estrogen-related receptors (ERRα, ERRβ, and ERRγ), a family of orphan nuclear receptors that regulate mitochondrial biogenesis, oxidative phosphorylation, and fatty acid metabolism. By binding the ligand-binding domain of all three ERR isoforms, SLU-PP-332 drives transcription of PGC-1α-coupled metabolic genes, producing an exercise-like signature in skeletal muscle. In preclinical mouse studies it has been shown to enhance endurance capacity by approximately 45–70% and reduce fat mass on high-fat diets without altering food intake or voluntary activity, supporting its classification as an exercise mimetic research compound.

SLU-PP-332 has a molecular formula of C27H25N3O4S and a molecular weight of 487.57 g/mol. The CAS registry number commonly associated with the compound is 2410279-67-7. It is a non-peptide small molecule built on a thiazole-acrylamide scaffold and is supplied as a crystalline solid. Because it is not a peptide, it does not have an amino acid sequence; researchers typically reference it by its SLU-PP-332 designation, as published by the Burris laboratory at Saint Louis University in 2023.

SLU-PP-332 should be stored as a lyophilized or crystalline powder at -20°C in a sealed container, protected from light and moisture. Under these conditions it is stable for at least 24 months. For in vitro work, the compound is typically dissolved in anhydrous DMSO at stock concentrations of 10–25 mM, then diluted into culture media just before use; the final DMSO concentration in cell assays should remain below 0.1%. For in vivo rodent studies in the published literature, SLU-PP-332 has been formulated in vehicles such as 15% Kolliphor HS-15 in saline. Stock DMSO solutions should be aliquoted and stored at -80°C to minimize freeze-thaw degradation.

SLU-PP-332, GW501516, and 5-Amino-1MQ all target oxidative metabolism but through distinct molecular mechanisms. GW501516 is a PPARδ agonist that increases fatty acid oxidation primarily in slow-twitch muscle fibers but has been associated with carcinogenicity findings in long-term rodent studies. 5-Amino-1MQ inhibits the enzyme NNMT to preserve NAD+ and SAM pools, indirectly supporting metabolic flexibility in adipocytes. SLU-PP-332 acts upstream at the transcriptional level by activating all three estrogen-related receptors, directly inducing mitochondrial biogenesis genes such as PGC-1α, NRF1, and TFAM. In published mouse models, SLU-PP-332 produced robust endurance gains and fat-mass reduction without the carcinogenic signal seen with GW501516, making it an actively investigated chemical probe for ERR biology.

No. The defining feature of SLU-PP-332 in preclinical research is that it activates exercise-like transcriptional programs in skeletal muscle and other oxidative tissues independent of physical activity. In sedentary mouse models, oral or intraperitoneal administration upregulates ERRα/β/γ target genes governing mitochondrial biogenesis, fatty acid oxidation, and oxidative phosphorylation, and increases running endurance when animals are subsequently challenged. This is why SLU-PP-332 is classified as an exercise mimetic — it engages the downstream metabolic program without requiring contractile stimulus.

AminoCore Research supplies SLU-PP-332 as a lyophilized small-molecule powder at ≥98% HPLC purity, with a Certificate of Analysis (COA) provided per lot. Common research-scale quantities range from 10 mg vials suitable for in vitro receptor assays and cell-culture work, up to larger 25-100 mg presentations appropriate for in vivo rodent pharmacology studies. All material is sold strictly for laboratory research use and is not intended for human or veterinary use.

Selectivity profiling has shown that SLU-PP-332 is a relatively selective pan-agonist of the estrogen-related receptors (ERRα, ERRβ, ERRγ) and does not directly bind the classical estrogen receptors (ERα, ERβ) or the glucocorticoid receptor that mediates cortisol signaling. Despite their name, ERRs do not bind estradiol — they are constitutively active orphan nuclear receptors regulated primarily by coactivators such as PGC-1α. This selectivity is one reason ERR agonists are of research interest as metabolic tools without the endocrine liabilities associated with steroid receptor modulators.

Published preclinical studies typically prepare SLU-PP-332 dosing solutions by first dissolving the compound in anhydrous DMSO to create a concentrated stock (commonly 25-50 mg/mL), then diluting into a co-solvent vehicle such as 5-10% DMSO / 40% PEG-400 / 5% Tween-80 / balance saline immediately before administration. Doses in mouse studies have ranged from approximately 10-50 mg/kg given orally or intraperitoneally, often once daily. Working dilutions should be prepared fresh, protected from light, and any precipitate addressed by gentle warming and brief sonication before injection.